Why CTSO Stock dropped -9.25% Today — RQD Quant Desk Flash

CTSO scores 22 out of 100, a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars: the Fundamental Cash Engine scores 4/20 (ROIC -35%; FCF yield 0%); Whale 13F Flow scores 5/20 (institutional accumulation and options positioning); Insider Conviction scores 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit scores 4/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet scores 6/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 2.82).

For a prospective investor, the pillar profile points to weak cash generation as the central issue: a negative ROIC and a 0% FCF yield mean the business is not currently converting capital into free cash for shareholders. The forensic pillar reflects a leveraged balance sheet (Debt/Equity 2.82) and a Piotroski F-Score of 3 out of 9, which signals limited financial-quality strength. The Insider and 13F pillars are also low, indicating weak conviction signals in the available flow data. The main upside driver implied by the data is any sustained improvement in operating income, since the reported operating margin of -39. The market capitalization of $13.9M against FY 2025 debt of $16.7M illustrates how thin the equity cushion appears relative to liabilities. The 52-week range of $2.84 - $17 reflects extreme price volatility, which is consistent with the rating's forensic-risk label.

Cytosorbents Corporation (CTSO) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. It is a Health Care issuer in this industry. —

Net losses narrowed from -$29.2M in FY 2023 to -$8.2M in FY 2025, while revenue rose from — to $37.1M across the same span. Gross margin is reported at 71.5%, but operating margin is -39.8% and net margin is -22.1%, with ROIC at -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 3 out of 9, with Debt/Equity at 2.82. These forensic readings indicate a balance sheet under meaningful strain with weak financial-quality signals.

• 🐂 Primary Bull Case: Revenue grew from $35.6M in FY 2024 to $37.1M in FY 2025 while net loss narrowed from -$20.7M to -$8.2M. With Fundamental Cash Engine at 4/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 5/20, sustained execution supports upside toward the top of the $2.84 – $17.00 52-week range.
• 🐻 Primary Bear Case: A negative 35% ROIC, 0% FCF yield, and a Debt/Equity of 2.82 against $13.9M market cap leave little equity cushion. Investors must weigh current valuation against -39.8% operating margins and a 1.00 macro beta if sector demand softens.

Upstream and downstream dependencies are — Sector correlation data beyond the Health Care sector and Medical/Dental Instruments industry classification is — Second-order bottlenecks are —

• Key Question #1: What is the composition of the FY 2025 debt of $16.7M, including maturity schedule and covenant terms?
• Key Question #2: What drove the revenue increase from $35.6M in FY 2024 to $37.1M in FY 2025, and what is the trajectory of operating losses?
• Key Question #3: Who holds the shares, and is there any analyst coverage or insider activity beyond the single WBB Securities initiation headline?